Corporate Europe Observatory (CEO)

LobbyFacts currently only presents data from the EU lobby transparency register up to 19 September 2021. This is due to recent changes made by the EU register; we are working to present these on LobbyFacts as soon as possible.

Tweet this page
How to read and use this data card.

Lobbying costs:

WARNING: As this organisation lists one or more EP accredited lobbyists, it is highly improbable that its lobbying costs are lower than €10,000.

WARNING: The lobbying costs declared by this organisation are extraordinarily high and may therefore have been over-declared.

100,000€ - 199,999€

Financial year: 01/01/2020 - 01/12/2020

Lobbyists declared: 2.75 FTE (10)

WARNING: The number of full time equivalent lobbyists declared by this organisation are extraordinarily high and may therefore have been over-declared.


Lobbyists with EP accreditation: 0

Meetings with European Commission: 1

Lobbying costs over the years:


Corporate Europe Observatory (CEO)

Registration on EU Transparency Register

5353162366-85 (First registered: 05 Sep 2008)

Goals / Remit

Corporate Europe Observatory (CEO) is a research and campaign group working to expose and challenge the privileged access and influence enjoyed by corporations and their lobby groups in EU policy making.

Corporate Europe Observatory is strongly committed to transparency about EU lobbying. CEO believes that the Transparency Register fails basic transparency standards and does not yet live up to its name. We support ALTER-EU's demand for a legally-binding register, stronger safeguards against inaccurate reporting, and the publication of the names of all individual interest representatives.

When registering, we have chosen to provide additional information that we consider necessary and relevant for lobbying transparency.


Issues covered in 2020-21: - The Commission work programmes for 2020 and 2021 - 2016-20 EU Transparency Register Review - Implementation of 2018 Code of Conduct for EU Commissioners - Implementation of 2014 European staff regulations - Implementation of Code of Conduct for MEPs, European Parliament’s revised Rules of Procedure, and increasing lobby transparency requirements for MEPs - Founding regulations, rules on conflicts of interest, transparency issues at EU agencies (including the European Food Safety Authority (EFSA) and the European Medicines Agency (EMA)) - Implementation of Rules of Procedure for Expert Groups - EU position at climate negotiations at the United Nations Framework Convention on Climate Change (UNFCCC) - Projects of Common Interest - EU trade policy, with a focus on EU foreign investment policy (including the Energy Charter Treaty), regulatory cooperation, the Comprehensive Economic and Trade Agreement between the EU and Canada (CETA), EU-US trade agreement, EU-UK trade agreement - Food, agriculture, GMO and pesticides policies and regulations - Horizon Europe (EU Research Funding Programme) - Scientific Advice Mechanism (SAM) - Short term rental platforms and the single market (gig economy) - European Central Bank ethics rules and asset purchases (quantitative easing) - Proposed directive on the enforcement of the Directive 2006/123/EC on services in the internal market, laying down a notification procedure for authorisation schemes and requirements related to services, COM(2016) 821 (also known as the Services notification procedure directive) - Proposal for a Directive of the European Parliament and of the Council on the reduction of the impact of certain plastic products on the environment - Classification of titanium dioxide and the French ban on food additive E171 - European Green Deal - Farm to Fork strategy - The e-Commerce Directive - EU strategy on the 'Collaborative Economy' - EU hydrogen Strategy - Trans European Networks for Energy (TEN-E) regulation - Climate Law - Common Agricultural Policy reform 2020 - Capital Requirements Directive - Strategy for Sustainable Finance - Regulations on medical devices and medical testing equipment - The European Semester and related procedures. - EU vaccines strategy and COIV19 response more generally - Corona crisis recovery funding In addition in 2020-21 we work to expose corporate lobbying on the following additional dossiers: Brexit; Banking regulation; Clinical Trials Directive and Innovative Medicines Initiative (IMI 2); Bio-Based Industries Joint Undertaking; Vehicle emissions review; endocrine disruptors regulation; development of the Economic and Monetary Union (including the 5 Presidents' report); consultancies lobbying for repressive regimes; privatisation of healthcare in Europe; threats to democracy emerging from the rise of billionaires in politics; EU medicines policy; Ethics rules and decision-making at the European Banking Authority including conflicts of interest, procedures on selection of chairman and director; the Coronavirus and the EU’s policy response; European Industrial Strategy; Smart Sector Integration Strategy; EU’s Chemicals Strategy for sustainability.


Head office:
Rue d'Edimbourg, 26
Brussels 1050

Tel: 32 28930930